A Randomized Open-Label Phase 2/3 Study of BT8009 as Monotherapy or in Combination in Participants with Locally Advanced or Metastatic Urothelial Cancer (DURAVELO-2)
Renal pelvis, ureter, bladder, and urethra
Beacon Hospital
PRINCIPAL INVESTIGATOR
Dato’ Dr Mohamed Ibrahim A Wahid
+603 – 7786 0845
dribrahim@beaconhospital.com.my